MS COSTAR: A computerized patient record adapted for clinical research purposes

Paty, Donald W.; Studney, D. R.; Redekop, William K.; Lublin, Fred

doi:10.1002/ana.410360732

Cited by 30 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The BC MS database was established in 1980 and collects information on MS patients seen at the four MS clinics in BC17 18; these clinics remained the only source of MS specialist care in the province until 2005. Clinical information including date of symptom onset and disease course was prospectively documented by clinic neurologists during visits and entered into the database.…”

Section: Methodsmentioning

confidence: 99%

Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada

Kingwell

Kop

Zhao

et al. 2011

J Neurol Neurosurg Psychiatry

139

122

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada

Kingwell

Kop

Zhao

et al. 2011

J Neurol Neurosurg Psychiatry

139

122

View full text Add to dashboard Cite

show abstract

“…Using this set of criteria, 24 patients had active multiple sclerosis and 17 patients had stable disease. In the second approach we identified 29 patients who were part of our systematic follow up system recorded using Costar14and had repeated evaluation with the Kurtzke extended disability status score (EDSS) after the lumbar puncture. The remaining 12 patients had not been included in this systematic follow up.…”

Section: Methodsmentioning

confidence: 99%

Cerebrospinal fluid concentrations of soluble CD27 in HTLV-I associated myelopathy and multiple sclerosis

Hintzen

Paty

Oger

1999

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

Objectives-Stimulation of T lymphocytes via the T cell receptor strongly enhances CD27 membrane expression and induces the release of a soluble 32 kDa form of CD27 (sCD27). CD27 is a member of the TNF receptor family, a group of molecules that have important roles in lymphocyte diVerentiation and survival. Raised concentrations of sCD27 have been reported in various immunopathological conditions and there is evidence that this molecule can serve as a marker of T cell activation in vivo. Concentrations of sCD27 in CSF were compared between patients with T cell mediated neurological disease and noninflammatory controls. Also, the relation of CSF-sCD27 concentrations with clinical disease activity was investigated in patients with multiple sclerosis. Methods-Four groups were studied: (1) eight patients with HTLV-1 associated myelopathy/ tropical spastic paraparisis (HAM)/TSP), (2) eight HTLV-I carriers, (3) 41 patients with multiple sclerosis, and (4) 43 patients with other neurological disease (OND). Concentrations of CSFsCD27 were determined by enzyme linked immunosorbent assay (ELISA). Results-Quantification of CSF-sCD27 diVerentiates patients with HAM/TSP from HTLV-I carriers (p<0.01) and from patients with OND (p<0.001). Moreover, the multiple sclerosis patient group was diVerent from the OND group (p<0.0001). In patients with multiple sclerosis, CSFsCD27 concentrations were higher in 24 patients with clinically active disease than in 17 with clinically stable disease. In addition, most of the patients with multiple sclerosis with high sCD27 concentrations showed an increase in EDSS, whereas none of the patients with low sCD27 had an EDSS increase. Conclusions-As a reliable marker of immunological disease activity in inflammatory white matter disease is still not available, it is proposed that quantification of CSF-sCD27 concentrations is a good candidate. Also, it may serve as a tool to stratify neurological diseases in inflammatory and non-inflammatory states. (J Neurol Neurosurg Psychiatry 1999;66:791-793)

show abstract

“…Sensory loss, predominantly in the limbs, is the most frequent initial complaint in MS, with visual loss and motor complaints common as well (16). However, patients may also complain of gait imbalance, bowel or bladder dysfunction, or even fatigue and a decline in cognitive function.…”

Section: Dr David Mccannmentioning

confidence: 99%